Ligand Pharma (LGND) Tops Q4 EPS by 9c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.27, $0.09 better than the analyst estimate of $1.18. Revenue for the quarter came in at $42.81 million versus the consensus estimate of $39.03 million.

GUIDANCE:

Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.14. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $188.8 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth